CoChat
Sign Up
Cited by 109Opioid Use Disorder TreatmentPrenatal Substance Exposure EffectsSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder

Wilder, Christine, Lewis, Daniel, Winhusen, Theresa·2015·Drug and Alcohol Dependence
DOI 10.1016/j.drugalcdep.2015.02.012
Open this paper in CoChat — free account

Abstract

Background Increasing use of opioids has led to an increase in the number of pregnant and postpartum women in medication assisted treatment (MAT) for opioid use disorder.Methods We (1) conducted a systematic review of published literature on MAT discontinuation (methadone and buprenorphine) in pregnant and postpartum women and (2) determined methadone discontinuation rates in a retrospective cohort (2006-2013) of pregnant and postpartum women in a university affiliated methadone clinic.Results We found limited generalizable literature reports of discontinuation rates, with a range of prenatal discontinuation rates from 0 to 33% and rates which spanned various prenatal and postnatal periods from 26 to 64%. In our cohort of 229 women, 251 pregnancies were reported, with a prenatal methadone discontinuation rate of 11.0%. Based on a Cox proportional hazards model controlling for age, pregnancy outcome, and duration of treatment prior to delivery, the probability of methadone discontinuation at or before 6 months postpartum was 56.0%. Duration of methadone treatment prior to delivery was inversely associated with risk for postpartum discontinuation of treatment (HR = 0.98, 95% CI (0.96, 0.99)).Conclusions We conclude that the postpartum period is a time of increased risk for discontinuation of MAT. More accurate assessment of rates of pre- and postpartum MAT discontinuation, as well as further investigation of factors affecting these rates, is warranted. Development and testing of interventions to encourage early prenatal enrollment in MAT and improve postnatal retention in MAT would benefit pregnant women and new mothers with opioid use disorder.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2015.02.012

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

Sorted by citations

Items 101–109 of 109

Related

See all

Metadata

Authors
Wilder, C., Lewis, D., & Winhusen, T.
Affiliations
  • United States Department of Veterans Affairs (US)
  • University of Cincinnati (US)
ORCID
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2015-04
Volume
149
Pages
225-231
ISSN
0376-8716 (ISSN-L)
DOI
10.1016/j.drugalcdep.2015.02.012
OpenAlex
W2033891285
Cited by
109
References
49
Citations by year
2026: 7 · 2025: 12 · 2024: 7 · 2023: 13 · 2022: 14 · 2021: 21 · 2020: 14 · 2019: 9 · 2018: 9 · 2017: 3
FWCI
0.58
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Drug and Alcohol Dependence (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
medication-assisted treatment, opioid use disorder, treatment discontinuation, pregnancy, postpartum period, methadone, buprenorphine, prenatal care, treatment duration, maternal health
MeSH terms
Buprenorphine, Female, Humans, Methadone, Narcotic Antagonists, Opioid-Related Disorders, Narcotics, Patient Dropouts, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Retrospective Studies, Postpartum Period, Kaplan-Meier Estimate, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review